Impact of Pharmacogenetics and Pregnancy on Tenofovir and Emtricitabine Pharmacokinetics

Aim:Treatment and prevention of mother-to-child transmission of HIV in pregnancy utilizes tenofovir (TFV) and emtricitabine (FTC) as NRTI backbone in combination with a third agent from a different class. We hypothesized that combined effect of pregnancy and pharmacogenetics significantly changes TFV and FTC pharmacokinetics (PK). Therefore, this study aims to evaluate the role of SNPs of transporters (ABCC2and ABCC4) on TFV and FTC PK during pregnancy. Method:61 pregnant or postpartum women on TFV and FTC were selected from a group of pregnant and postpartum Nigerian women and both SNPs and drug levels were evaluated. Results:Pregnancy decreases TFV plasma concentration by 26% (log10β = -0.131 [-0.228, -0.034; p = 0.009] at median [range] time-point postdose 14 [7–18.5h]). FTC concentration in individuals with ABCC212:g.154962860T>C TT genotype were one- to twofold higher than heterozygous (CT) and homozygous (CC) women. All other evaluated SNPs were not significant. Conclusion:Pregnancy decreased TFV concentration and significant relationship was found between FTC and ABCC212:g.154962860T>C wild-type allele. However, the interplay between pregnancy and pharmacogenetics on TFV and FTC PK is unclear but require further evaluation.